Skip to main content
Medical Gas Research logoLink to Medical Gas Research
. 2018 Jan 22;7(4):273–276. doi: 10.4103/2045-9912.222452

The role of nitrous oxide in stroke

Zhu-wei Zhang 1,#, Dong-ping Zhang 1,#, Hai-ying Li 1,#, Zhong Wang 1,*, Gang Chen 1,*
PMCID: PMC5806449  PMID: 29497489

Abstract

Stroke that is caused by poor blood flow into the brain results in cell death, including ischemia stroke due to lack of blood into brain tissue, and hemorrhage due to bleeding. Both of them will give rise to the dysfunction of brain. In general, the signs and symptoms of stroke are the inability of feeling or moving on one side of body, sometimes loss of vision to one side. Above symptoms will appear soon after the stroke has happened. If the symptoms and signs happen in 1 or 2 hours, we often call them as transient ischemic attack. Moreover, hemorrhagic stroke often leads to severe headache. It is known that neuronal death can happen after stroke, and it depends upon the activation of N-methyl-D-aspartate (NMDA) excitatory glutamate receptor which is the goal for a lot of neuroprotective agents. Nitrous oxide was discovered by Joseph Priestley in 1772, and then he and his friends, including the poet Coleridge and Robert Sauce, experimented with the gas. They found this gas could make patients loss the sense of pain and still maintain consciousness after inhalation. Shortly the gas was used as an anesthetic, especially in the field of dentists. Now, accroding to theme of Helene N. David and other scientists, both of nitrous oxide at 75 vol% and xenon at 50 vol% could reduce ischemic neuronal death in the cortex by 70% and decrease NMDA-induced Ca2+ influx by 30%. Therefore, more clinical and experimental studies are important to illuminate the mechanisms of how nitrous oxide protects brain tissue and to explore the best protocol of this gas in stroke treatment.

Keywords: nitrous oxide, experimental research, clinical research, ischemia, neuroprotective effects, anesthetics

INTRODUCTION

Stroke is defined as a sudden neurological pathological sign and always has been considered as a significant leading factor of death and disability in the world.1 The high morbidity and mortality of this catastrophic illness make our society and family bear a huge burden2; what's more, what is causing it becomes a public health issue and wait to settle pressingly. In addition, with increasing of population in many industrialized countries, the severity of stroke rise up year by year, therefore this problem must be thought highly by all of us. Generally speaking, stroke can be divided into ischemic accounting for approximate 80% of them and hemorrhagic stroke.3 Currently many studies have shown that it is nitrous oxide at subanesthetic concentrations that may have larvaceously neuroprotective and therapeutic characters, so we can focus on their beneficial effects to settle the issue of ischemia-induced neuronal death.4

Nitrous oxide is the most commonly used anesthetic that has been used for the inhalation and maintenance of anaesthesia for over 160 years, because of low cost, low tissue solubility, and low rate of cardiorespiratory complications. Nitrous oxide that is a relatively weak anaesthetic gas should need to be inhaled in high concentrations which restrict oxygen delivery (such as a common mixture is 30% oxygen with 70% nitrous oxide).5 Many studies have shown that the nitrous oxide metabolic effects are linked to elevated plasma homocysteine levels and endothelial dysfunction perioperatively,4,6 and nitrous oxide may possess potentially neuroprotective ability in animal models.4,7 However, nitrous oxide also has neurotoxic and pro-neurotoxic action under other certain conditions,8,9,10,11 so in this article, we will discuss the influence of nitrous oxide for stroke injury and the potential mechanisms on the basis of experimental and clinical studies to explore the feasibility of treatment.

MECHANISM OF NITROUS OXIDE IN STROKE

Glutamate is a common neurotransmitter that plays an important role in many physiological functions.12 However, under a lot of pathological conditions, neurons will become so sensitive to glutamate, and the glutamate also can damage or kill them, mainly through N-methyl-D-aspartate (NMDA) receptor that can mediate calcium influx,13 Blocking the NMDA receptor which always be thought to be inhibited by nitrous oxide and then excitotoxicity may help to decrease damage and dysfunctions of central nervous system to avoid disorders.14 With many investigations, nitrous oxide and xenon, which are safe anesthetics, have been demonstrated to be effective inhibitors of the NMDA receptor,15,16,17 and to have a pharmacological character that resembles as NMDA receptor antagonist in low-affinity use.17 The gases could cross over the blood-brain barrier, and has low blood/gas solubility that is propitious in terms of rapid absorbed and expelled (conditions that may be beneficial for treatment and reduce risk of neurotoxicity), so the nitrous oxide have been recently shown to possess therapeutic characters (Figure 1).4

Figure 1.

Figure 1

The mechanisms of nitrous oxide in the stroke.

Note: NMDAR: N-methyl-D-aspartate receptor.

EXPERIMENTAL STUDIES OF NITROUS OXIDE IN STROKE

As for animal experiment, animal models of hemorrhagic and ischemic stroke, especially ischemic stroke, were successfully established, then the gas of nitrous oxide was applied to treat the subject after stroke insult, and finally the researchers detected the effects of nitrous oxide on stroke and explored the potential mechanisms by which the gas protected nervous system. As we known, animal experiment belongs to basic medical research or preclinical research and most of them were aimed to investigate the mechanism of objective gas in neurological influence following stroke.

The conclusion of these studies may be different owing to different experimental conditions and methods. We analyze several recent experimental studies related to this gas for stroke treatment in this paper (Table 1), and summarize the outcomes.

Table 1.

The neuroprotective effects of hydrogen nitrous oxide in stroke

graphic file with name MGR-7-273-g002.jpg

So after analyzing of the above experimental results, the effect of nitrous oxide to neuropsychological functions has been some areas of controversy, so do in animal models. Some research has already demonstrated preferable outcomes, while others show detrimental results.7,21,24,25 Unfortunately, only a little of randomized controlled experiment have illustrate functional outcomes. Most of them were limited to neurological outcome, according to cardiopulmonary bypass.26,27,28 In theory, nitrous oxide can increase rate of cerebral metabolism, cerebral blood flow, and intracranial pressure.29 Nitrous oxide also has the potential to give rise to intracranial air volume.30,31 However, many studies demonstrate that nitrous oxide at 75 vol% and xenon at 50 vol% can reduce cortical brain damages in vivo, and decrease NMDA-evoked Ca2+ influxes of neuronal cell, which is a process which is considered as a major primary event involved in the excitotoxic neuronal death.32 The neuroprotective action of nitrous oxide at 75 vol% and of xenon at 50 vol% after middle cerebral artery occlusion (MCAO) in vivo may account for their pharmacologically antagonistic properties at the NMDA receptor,33 because the gas have no effect to the α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor.17 So many dates of studies have shown that nitrous oxide and xenon keep normal cells from excitotoxic neuronal death produced by stimulating either glutamate or NMDA in cortical cell cultures.34 The neuroprotective effects of nitrous oxide were found at subanesthetic concentrations corresponding to 0.6 minimum alveolar concentration, which did not bring suppression of locomotor activity, as assessed by the observation of the behavior of the freely moving animals.18 These protective effects of nitrous oxide manifest to be timing-sensitive, and with a relative narrow therapeutic window that exists within 2 hours following MCAO. When administered at 3 hours after MCAO, nitrous oxide increased infarct volume, appearing to be neurotoxicity.18 Based upon these facts, we believe that nitrous oxide at 75 vol% and of xenon at 50 vol% may be beneficial for the stroke of treatment of human.

CLINICAL STUDIES OF NITROUS OXIDE IN STROKE

A post hoc analysis of a subset of data, which comes from the intraoperative hypothermia for aneurysm surgery trial, showed that the use of nitrous oxide in neurosurgery was associated with an increasing risk of developing delayed ischemic neurological deficits in patients with cerebral aneurysms, but with absence of longterm gross neurologic or neuropsychological damage.35 Counterintuitively, the patients that inhaled nitrous oxide were also at risk for neuropsychological impairment on at least one test.36 In addition, as same to other anesthetics, nitrous oxide can cause hypothermia,37 which can downregulate the release of glutamate, glycine and so does inhibit oxidation.38

POSSIBLE THERAPEUTIC IMPLICATIONS

According to the data of the present studies, there are an increasing number of evidences that nitrous oxide and xenon may have potentially neuroprotective and therapeutic abilities for the treatment and be beneficial for protection of brain tissue, even if xenon at concentrations of 75 vol% further appear to be potentially neurotoxic properties and adverse side effects. In contrast, xenon at 50 vol% will reduce neuronal cells death, when administered as post-treatment after MCAO in the rat, and it will reduce NMDA-evoked Ca2+ influxes in neuronal cell cultures; accordingly, xenon at an about concentration (approximately 40 vol%) could be considered as a potentially therapy for the treatment of stroke in humans. Now, what is the most major reason is that clinical use of xenon is the expensive cost of production, but we think combination of both of nitrous oxide and xenon will solve this problem. Finally we believe that nitrous oxide will open up a new path to protect the nervous system.

Footnotes

Conflicts of interest

The authors declare that they have no competing interests.

Plagiarism check

Checked twice by iThenticate.

Peer review

Externally peer reviewed.

Oper peer reviewer

Wen-wu Liu, Second Military Medical University, China.

Funding: This work was supported by Suzhou Key Medical Center (Szzx201501), grants from the National Natural Science Foundation of China (No. 81571115, 81422013, 81471196), Scientific Department of Jiangsu Province (No. BL2014045), Suzhou Government (No. SZS201413, SYS201608, and LCZX201601), and Jiangsu Province (No. 16KJB320008).

REFERENCES

  • 1.Bath PM, Lees KR. ABC of arterial and venous disease. Acute stroke. BMJ. 2000;320:920–923. doi: 10.1136/bmj.320.7239.920. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Edwards JD, Kapral MK, Fang J, Swartz RH. Trends in Long-Term Mortality and Morbidity in Patients with No Early Complications after Stroke and Transient Ischemic Attack. J Stroke Cerebrovasc Dis. 2017;26:1641–1645. doi: 10.1016/j.jstrokecerebrovasdis.2016.09.038. [DOI] [PubMed] [Google Scholar]
  • 3.Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors. Neurol Clin. 2008;26:871–895. doi: 10.1016/j.ncl.2008.07.003. vii. [DOI] [PubMed] [Google Scholar]
  • 4.Abraini JH, David HN, Lemaire M. Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon. Ann N Y Acad Sci. 2005;1053:289–300. doi: 10.1196/annals.1344.025. [DOI] [PubMed] [Google Scholar]
  • 5.Sun R, Jia WQ, Zhang P, et al. Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia. Cochrane Database Syst Rev. 2015 doi: 10.1002/14651858.CD008984.pub2. CD008984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ko H, Kaye AD, Urman RD. Nitrous oxide and perioperative outcomes. J Anesth. 2014;28:420–428. doi: 10.1007/s00540-013-1729-y. [DOI] [PubMed] [Google Scholar]
  • 7.David HN, Leveille F, Chazalviel L, et al. Reduction of ischemic brain damage by nitrous oxide and xenon. J Cereb Blood Flow Metab. 2003;23:1168–1173. doi: 10.1097/01.WCB.0000087342.31689.18. [DOI] [PubMed] [Google Scholar]
  • 8.Jevtovic-Todorovic V, Beals J, Benshoff N, Olney JW. Prolonged exposure to inhalational anesthetic nitrous oxide kills neurons in adult rat brain. Neuroscience. 2003;122:609–616. doi: 10.1016/j.neuroscience.2003.07.012. [DOI] [PubMed] [Google Scholar]
  • 9.Mullenix PJ, Moore PA, Tassinari MS. Behavioral toxicity of nitrous oxide in rats following prenatal exposure. Toxicol Ind Health. 1986;2:273–287. doi: 10.1177/074823378600200306. [DOI] [PubMed] [Google Scholar]
  • 10.Jevtovic-Todorovic V, Carter LB. The anesthetics nitrous oxide and ketamine are more neurotoxic to old than to young rat brain. Neurobiol Aging. 2005;26:947–956. doi: 10.1016/j.neurobiolaging.2004.07.009. [DOI] [PubMed] [Google Scholar]
  • 11.Ma D, Williamson P, Januszewski A, et al. Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain. Anesthesiology. 2007;106:746–753. doi: 10.1097/01.anes.0000264762.48920.80. [DOI] [PubMed] [Google Scholar]
  • 12.Zimmerman JE, Chan MT, Lenz OT, Keenan BT, Maislin G, Pack AI. Glutamate Is a Wake-Active Neurotransmitter in Drosophila melanogaster. Sleep. 2017:40. doi: 10.1093/sleep/zsw046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Manev H, Favaron M, Candeo P, Fadda E, Lipartiti M, Milani D. Macrolide antibiotics protect neurons in culture against the N-methyl-D-aspartate (NMDA) receptor-mediated toxicity of glutamate. Brain Res. 1993;624:331–335. doi: 10.1016/0006-8993(93)90098-8. [DOI] [PubMed] [Google Scholar]
  • 14.Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 1998;11:523–569. doi: 10.1358/dnp.1998.11.9.863689. [DOI] [PubMed] [Google Scholar]
  • 15.Jevtović-Todorović V, Todorović SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4:460–463. doi: 10.1038/nm0498-460. [DOI] [PubMed] [Google Scholar]
  • 16.Goto T, Nakata Y, Morita S. How does xenon produce anesthesia? A perspective from electrophysiological studies. Int Anesthesiol Clin. 2001;39:85–94. doi: 10.1097/00004311-200104000-00009. [DOI] [PubMed] [Google Scholar]
  • 17.Yamakura T, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology. 2000;93:1095–1101. doi: 10.1097/00000542-200010000-00034. [DOI] [PubMed] [Google Scholar]
  • 18.Haelewyn B, David HN, Rouillon C, et al. Neuroprotection by nitrous oxide: facts and evidence. Crit Care Med. 2008;36:2651–2659. doi: 10.1097/CCM.0b013e318183f646. [DOI] [PubMed] [Google Scholar]
  • 19.Bedforth NM, Girling KJ, Harrison JM, Mahajan RP. The effects of sevoflurane and nitrous oxide on middle cerebral artery blood flow velocity and transient hyperemic response. Anesth Analg. 1999;89:170–174. doi: 10.1097/00000539-199907000-00030. [DOI] [PubMed] [Google Scholar]
  • 20.Yokoo N, Sheng H, Mixco J, Homi HM, Pearlstein RD, Warner DS. Intraischemic nitrous oxide alters neither neurologic nor histologic outcome: a comparison with dizocilpine. Anesth Analg. 2004;99:896–903. doi: 10.1213/01.ANE.0000132973.32387.8B. table of contents. [DOI] [PubMed] [Google Scholar]
  • 21.Abraini JH, David HN, Nicole O, MacKenzie ET, Buisson A, Lemaire M. Neuroprotection by nitrous oxide and xenon and its relation to minimum alveolar concentration. Anesthesiology. 2004;101:260–261. doi: 10.1097/00000542-200407000-00049. author reply 261. [DOI] [PubMed] [Google Scholar]
  • 22.Bruder N. Anaesthesia for patients with intracranial hypertension due to cerebral oedema. Ann Fr Anesth Reanim. 2003;22:226–234. doi: 10.1016/s0750-7658(03)00011-x. [DOI] [PubMed] [Google Scholar]
  • 23.Sugaya T, Kitani Y. Nitrous oxide attenuates the protective effect of isoflurane on microtubule-associated protein2 degradation during forebrain ischemia in the rat. Brain Res Bull. 1997;44:307–309. doi: 10.1016/s0361-9230(97)00142-1. [DOI] [PubMed] [Google Scholar]
  • 24.Baughman VL, Hoffman WE, Thomas C, Albrecht RF, Miletich DJ. The interaction of nitrous oxide and isoflurane with incomplete cerebral ischemia in the rat. Anesthesiology. 1989;70:767–774. doi: 10.1097/00000542-198905000-00011. [DOI] [PubMed] [Google Scholar]
  • 25.Baughman VL. N2O: of questionable value. J Neurosurg Anesthesiol. 1995;7:79–81. [PubMed] [Google Scholar]
  • 26.Nussmeier NA, Arlund C, Slogoff S. Neuropsychiatric complications after cardiopulmonary bypass: cerebral protection by a barbiturate. Anesthesiology. 1986;64:165–170. doi: 10.1097/00000542-198602000-00006. [DOI] [PubMed] [Google Scholar]
  • 27.Zaidan JR, Klochany A, Martin WM, Ziegler JS, Harless DM, Andrews RB. Effect of thiopental on neurologic outcome following coronary artery bypass grafting. Anesthesiology. 1991;74:406–411. doi: 10.1097/00000542-199103000-00003. [DOI] [PubMed] [Google Scholar]
  • 28.Roach GW, Newman MF, Murkin JM, et al. Ineffectiveness of burst suppression therapy in mitigating perioperative cerebrovascular dysfunction. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Anesthesiology. 1999;90:1255–1264. doi: 10.1097/00000542-199905000-00006. [DOI] [PubMed] [Google Scholar]
  • 29.Tsai YC, Lin SS, Lee KC, Chang CL. Cerebral effects of nitrous oxide during isoflurane-induced hypotension in the pig. Br J Anaesth. 1994;73:667–672. doi: 10.1093/bja/73.5.667. [DOI] [PubMed] [Google Scholar]
  • 30.Hernández-Palazo NJ, Nuño de la Rosa-Carrillo V, Martínez-Lage JF, López-Hernández F, Pérez-Espejo MA. Tension pneumocephalus after intracranial surgery in the supine position. Neurocirugia (Astur) 2004;15:596–599. doi: 10.1016/s1130-1473(04)70452-2. [DOI] [PubMed] [Google Scholar]
  • 31.Domino KB, Hemstad JR, Lam AM, et al. Effect of nitrous oxide on intracranial pressure after cranial-dural closure in patients undergoing craniotomy. Anesthesiology. 1992;77:421–425. doi: 10.1097/00000542-199209000-00003. [DOI] [PubMed] [Google Scholar]
  • 32.Dincman TA, Beare JE, Ohri SS, Gallo V, Hetman M, Whittemore SR. Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo. Int J Dev Neurosci. 2016;54:53–61. doi: 10.1016/j.ijdevneu.2016.08.006. [DOI] [PubMed] [Google Scholar]
  • 33.Abraini JH, Rostain JC, Kriem B. Sigmoidal compression rate-dependence of inert gas narcotic potency in rats: implication for lipid vs. protein theories of inert gas action in the central nervous system. Brain Res. 1998;808:300–304. doi: 10.1016/s0006-8993(98)00760-4. [DOI] [PubMed] [Google Scholar]
  • 34.Ma D, Wilhelm S, Maze M, Franks NP. Neuroprotective and neurotoxic properties of the ‘inert’ gas, xenon. Br J Anaesth. 2002;89:739–746. [PubMed] [Google Scholar]
  • 35.Jiang D, McAlpine D, Palmer AR. Responses of neurons in the inferior colliculus to binaural masking level difference stimuli measured by rate-versus-level functions. J Neurophysiol. 1997;77:3085–3106. doi: 10.1152/jn.1997.77.6.3085. [DOI] [PubMed] [Google Scholar]
  • 36.Deng J, Lei C, Chen Y, et al. Neuroprotective gases--fantasy or reality for clinical use? Prog Neurobiol. 2014;115:210–245. doi: 10.1016/j.pneurobio.2014.01.001. [DOI] [PubMed] [Google Scholar]
  • 37.Alex J, Laden G, Cale AR, et al. Pretreatment with hyperbaric oxygen and its effect on neuropsychometric dysfunction and systemic inflammatory response after cardiopulmonary bypass: a prospective randomized double-blind trial. J Thorac Cardiovasc Surg. 2005;130:1623–1630. doi: 10.1016/j.jtcvs.2005.08.018. [DOI] [PubMed] [Google Scholar]
  • 38.Weng Y, Sun S. Therapeutic hypothermia after cardiac arrest in adults: mechanism of neuroprotection, phases of hypothermia, and methods of cooling. Crit Care Clin. 2012;28:231–243. doi: 10.1016/j.ccc.2011.10.012. [DOI] [PubMed] [Google Scholar]

Articles from Medical Gas Research are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES